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Despite the progress in techniques for cancer prevention,
detection, and treatment, as well as for increasing the public
awareness in recent years, this disease is projected to become
the leading cause of death worldwide. Advancements in
omics, analytical procedures, and high throughput screening
in the last five years have led to the realization that human
diseases and especially cancer are more complex than were
originally conceived. Cancer is not a static entity that can
be easily monitored and manipulated. It is characterized
by a dynamic and time-dependent network of constantly
altered molecular and cellular interactions between players
in different pathways. This network is not invariable and
rigid but is constantly reshaped and altered conforming
to the pliable signaling processes/responses implicated. Its
complexity is apparent by the fact that the disease state is not
a disruption of a single node or specific nodes in the network
organism but is organism-patient dependent, thus requiring
personalized perspective approaches.
Numerous challenges hamper effective cancer treatment
and development of effective drugs such as ineffective ther-
apeutic drug concentration reaching the tumor site, life-
threatening side-effects caused by nonspecific tissue distri-
bution of anticancer agents, and acquired resistance of the
cancer cell upon chemotherapy that triggers cross-resistance
to a wide range of different drugs.
Such multifactorial states require the development of
very delicate approaches in the course of the drug discovery
pipeline. The scientific roots of the drug development phi-
losophy should be shifted from the traditional concept of the
“magic bullet” drug (i.e., scalped for a single drug target) to
the formulation of a navigated vehicle which could spatio-
temporally deliver the drug in the correct location and the
appropriate time.Thus, the term targeted drug delivery should
give its place to navigated drug delivery since it is not only
the cytotoxic drug that targets a specific cellular location but
rather a vehicle that navigates the course of the loaded drug to
the appropriate site of action. Such drug loaded and navigated
vehicles in order to enhance the selective uptake of the
cytotoxic agent by the tumor cells and spare the normal cells,
should consist of a multidimensional architecture (Figures
1 and 2). The major components of these vehicles are the
transporting vehicle (i.e., lipid), the cytotoxic agent that
is loaded, the “programmable” navigating/targeting agent
(i.e., receptor specific ligand) that enables the appropriate
delivery routes to avoid toxicity on healthy proliferating
cells as also ineffective concentration of the cytotoxic agent
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Figure 1: Structural architecture and mechanical analogue of a navigated drug delivery nanoparticle.
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Figure 2: Navigated drug delivery: the drug delivery vehicle is equipped with a “programmable navigation system” that allows the
transportation of the “blind” cytotoxic agent in the correct cellular location. In the absence of the drug delivery vehicle that is tagged with
navigating delivery routes, toxicity is triggered on healthy proliferating cells against the anticancer agent, and ineffective therapeutic drug
concentration reaches the tumor site.
to the tumor site (Figure 2), and the “stealth” nanocarriers
(biocompatibility polymers, i.e., PEG) that enhance the short
plasma half-life of the drug-loaded transporting vehicle.
In line with the challenges raised by the complexity of
cancer, the aim of the present thematic issue is to provide
an accumulation of innovative molecularly targeted cancer
therapies and entrepreneurial methods of drug delivery
in cancer (Table 1). It contains 12 papers embracing most
aspects of cancer related to the exploration of active targeted
nanoparticles for cancer treatment and diagnosis, including
the exploitation of novel cancer drug targets, vaccine design
against cancer, innovative methods for drug delivery-based
on focused ultrasound or convection enhanced delivery, and
mathematical modeling as an indispensable tool to analyze
the transport processes and predict the outcome of anticancer
treatment.
A constant developmental effort is being conducted
for innovative nanoparticles to meet unmet needs in the
transportation of imaging and therapeutic agents for cancer
diagnosis and therapy. This happens since the nanoscale of
these particles allows sculpting of diversity in their capa-
bilities thus, enabling them to respond to a diverse array
of functional requirements. Therefore, nanoparticles have
been considered as appropriate vehicles to provide an ideal
platform for personalized approaches to cancer diagnosis and
therapy in cancer disease management. A. D. Miller presents
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Table 1: Some of the delivery systems appeared in this issue.
Vehicle Vehicle description Navigation device Target location Cancer type
Bionanocapsules
A bionanocapsule (BNC) is a
hollow nanoparticle consisting of an
approximately 100 nm diameter
liposome with about 110 molecules
of hepatitis B virus (HBV) surface
antigen L protein embedded as a
transmembrane protein.
Chlorotoxin MMP-2 protein Brain tumor
Enzyme-based cancer
imaging agents
Dual aromatase-steroid sulfatase
inhibitor (DASSI) radiotracers
11C-labelled inhibitors
of steroid sulfatase
(sulfamate derivatives)
Enzymes of the
“sulfatase pathway”,
particularly steroid
sulfatase
Breast, endometrial,
ovarian, and
colorectal cancer
Cytotoxic drugs
coupled to
OATP-substrates or
OATP-directed
antibodies
Substrates of membrane-located
OATP isoforms, selectively
expressed in cancer cells, for
example, microcystins as substrates
for OATP1B3
Selective ligands for
OATP for example,
microcystins
or OATP-directed
antibodies in cancer
cells
Organic anion
transporting
polypeptides (OATPs)
Gastrointestinal tract,
breast, prostate, lung,
brain, bladder, kidney,
liver, testis
Lipid-based
nanoparticles
Genuine particles (approx 100 nm
in dimension) assembled from
varieties of lipid and other chemical
components that act collectively to
overcome biological barriers
(biobarriers)
Bona fide biological
receptor specific
ligands
PEGylated Span 80
vesicles PEGylated
Span 80 vesicles with
immobilized ESA
Span 80 is a heterogeneous mixture
of sorbitan mono-, di-, tri-, and
tetra-esters
Lectin-sugar binding
protein (Eucheuma
serra agglutinin)
Sugar chains on the
tumor cell-surface Osteosarcoma
Doxorubicin
(DOX)-loaded
liposomes
Liposomes composed of DSPG,
DSPC, cholesterol, and
DSPE-PEG-2000
A triple-helical
sequence derived from
type IV
collagen
CD44/chondroitin
sulfate proteoglycan
CD44-overexpressing
tumor cells
Mannan
Oxidized or reduced mannan, a
poly-mannose, conjugated to cancer
antigen
Mannan Mannose receptor Adenocarcinoma
a rigorous and descriptive overview on the status of lipid-
based nanoparticles (LNPs) in cancer diagnosis and therapy.
Special focus is given on LNPs that conform to the ABCD
nanoparticle structural paradigm (A: active pharmaceutical
ingredient, B: lipids, C: a stealth/biocompatibility polymer
layer (like PEG), D: targeting layer-receptor specific ligand)
and to triggered, multimodal imaging theranostic drug-
nanoparticles for cancer therapy.
Clinical attrition rates are a critical issue in drug develop-
ment. In oncology, fourfold higher rates of attrition have been
determined in respect of other indications. This clearly pin-
points the unmet necessity to steer for novel and traditionally
unexplored drug targets to be employed in the drug discovery
process towards the development of novel anticancer drugs.
In this light, V. Buxhofer-Ausch et al. describe the capacity
of members of the organic anion transporter family (OATP)
to serve as tumor biomarkers and effective cancer drug
targets. The importance of these drug targets is due to
their implication on the uptake of clinically important drugs
and hormones, thereby affecting drug disposition and cell
penetration. An OATP-targeted therapy holds promises to
combat cancer efficiently and with lesser side effects due to
the tissue specific expression of different OATPmembers and
specifically their differential expression in various cancer and
normal tissues.
Enzymes of the sulfatase pathway could offer another
appealing cancer drug target. S. Lena et al. provide a compre-
hensive review about the expression and function of enzymes
of the sulfatase pathway, particularly of steroid sulfatase
(STS), in breast, endometrial, ovarian, and colorectal cancer.
Furthermore, it highlighted the applicability of STS inhibitors
to function as enzyme-based cancer imaging agents applied
in the biomedical imaging technique positron emission
tomography for the diagnosis and therapy of estrogen-
sensitive cancers.
Since cancer is considered not only as a genetic but also
as an epigenetic disease and tumorigenesis involves multiple
genetic and epigenetic alterations that contribute to the trans-
formation of normal cells towards a malignant phenotype,
epigenetics should also be the focus of discovering novel
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cancer drug targets. E. Hatzimichael and T. Crook reviewed
important advances in the field of cancer epigenetics and
specifically provide an overview of the clinical use of epi-
genetics as cancer biomarkers and current progress in the
utilization of epigenetic drugs in solid and blood cancers.
Navigated delivery of cytotoxic agents to special sites or
organs is a challenging issue that needs to be addressed in
order to surpass systematic toxicity.These challenges become
even more exigent for drug delivery in brain tumors where
intrinsic difficulties are met due to the hurdles faced to
cross the brain-tumor and blood-brain barriers. To establish
a targeting vehicle for glioblastoma cells, T. Kasai et al.
exploited the capability of chlorotoxin to selectively bind to
matrix metalloproteinase-2 and other proteins on glioma cell
surfaces once it was fused to human IgG-Fcs and displayed
on the surface of bionanocapsules. This chlorotoxin loaded
bionanocapsule showed specific affinity to the surface of
glioma cells and internalized into the cytoplasmic space
suggesting that is a promising drug delivery system for
targeting glioblastoma.
In order to establish a target-based agent to be specifically
delivered to osteosarcomas, K. Hayashi et al. focused on a
lectin (Eucheuma serra agglutinin) both as a tumor-targeting
agent and as an antitumor agent. Lectins are carbohydrate
binding proteins that are highly specific for sugar moieties
on the surface of tumor cells. The authors formulated a drug
delivery system containing PEGylated Span 80 vesicles which
immobilized the specific lectin. They noted that the specific
system was not only selectively targeting osteosarcoma cells
but was also cytotoxic to the targeted cells emphasizing the
dual role adopted by lectins both as navigating and cytotoxic
agents.
To achieve an effective approach for enhanced uptake
of anticancer drug-loaded vehicles by tumor cells, M. W.
Ndinguri et al. explored cell surface proteoglycan CD44
targeting as a way to selectively deliver therapeutic agents
encapsulated inside colloidal delivery systems. CD44 has
been recognized as a contributor to tumor chemoresistance
and as a cancer cell and cancer stem cell biomarker due
to its overexpression in cancer compared to normal cells
(haematopoietic, epithelial, and neuronal cells). To target
CD44, the authors used a triple-helical peptide sequence
derived from type IV collagen that was incorporated in
doxorubicin-loaded liposomes (composed of DSPG, DSPC,
cholesterol, and DSPE-PEG-2000). The CD44-targeted lipo-
somes were found effective in reducing tumor size, highlight-
ing their potential to be used for selective chemotherapeutic
treatment of CD44 overexpressing tumor cells.
The immune system has evolved to protect the body
against microorganism invasion and thereby prevent dis-
eases. Thus, cancer vaccines could boost the immune system
to enable it to combat cancer more effectively. In vaccine
development, a major aim is to induce strong, specific T
cell responses. This is achieved by targeting antigens to cell
surface molecules on dendritic cells (DCs) that efficiently
stimulate T cell responses. The paper by V. Apostolopoulos
et al. focuses on the most attractive cell surface receptors
expressed on DCs to be used as targets for antigen delivery
for cancer immunotherapy. The DC cell surface receptors
(receptor kinases, Toll-like receptors, andC-type lectin recep-
tors) which induce cellular responses and show promise as
targets for vaccine design against cancer are highlighted.
Along these lines, K.-C. Sheng et al. investigated the effect of
IFN-gamma onDC functionalmaturation andDCmeditated
helper T cell activation, in the presence and absence of Toll-
like receptor (TLR) ligation. The authors demonstrated an
adjuvant effect of IFN-gamma on DC maturation and T
cell stimulation and proposed a novel use of IFN-gamma
together with Toll-like receptor agonists to enhance antigen-
specific T cell responses, for applications in the development
of enhanced vaccines and drug targets, against diseases,
including cancer.
An alternative to the systemic drug delivery is the
convection-enhanced delivery (CED) on the basis of which
agents are delivered directly into the tumor and the surround-
ing infiltrative edges with continuous, positive-pressure infu-
sion, thus allowing direct access to the tumor bed, achieving
high local concentrations of the drug with minimal systemic
absorption. The paper by J. Yun et al. focuses on the authors
preclinical and clinical experience with CED in glioblastoma
and highlight the challenges and potency of this methodol-
ogy. Special emphasis is given onto the translational goals of
this work.
M. Thanou and W. Gedroyc provided a comprehensive
overview on the utilization of MRI-guided focused ultra-
sound (MRgFUS) as a new method of drug delivery. This
methodology combines a high intensity focused ultrasound
beam that can be used as an external stimulus to activate
drug delivery in tissues and Magnetic Resonance Imaging
system (MRI) which visualizes patient anatomy and controls
the treatment by continuously monitoring the tissue effect.
The advantages of being noninvasive as well as controlled
and focus could establish this methodology as valuable tool
in clinic to increase drug targeting and tissue specific drug
delivery.
The transport of anticancer drugs and their consequence
on tumor cells implicates an array of physical and bio-
chemical processes. Since multiple steps are involved in
the drug-transport, drug-release, and drug-uptake pipelines,
mathematical models have become an indispensible tool to
analyze the transport processes and predict the outcome
of anticancer treatment. Mathematical modeling of cancer
provides a tool to assist our realization on the interaction and
drug-mediated perturbation of such complex processes, thus,
fruitfully contributing to the optimization and refinement of
drug delivery. W. Zhan and X. Y. Xu present the development
of an improved mathematical model that was applied to an
idealized geometry consisting of tumor and normal tissues.
They predicted the efficacies of direct intravenous adminis-
tration and thermosensitive liposome-mediated delivery and
illustrated that thermo-sensitive liposome-mediated delivery
provides a lower drug concentration in normal tissues than
direct infusion of non-encapsulated drug as also a signifi-
cantly higher peak intracellular concentration. These com-
putational results furnish a projection on the effectiveness of
two different treatments, within a mathematical framework,
and set the basis to develop and corroborate optimized
treatments with reduced risk of associated side effects as also
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effective tumor cell killing in a short time period of treat-
ment.
Due to the complexity of the disease, efficient cancer ther-
apy can emerge only upon interscience collaboration. This
special issue aims to accumulate current knowledge on
molecularly targeted cancer therapies and innovative meth-
ods of drug delivery in cancer. We believe that this accumu-
lative knowledge will assist to accelerate progress developing
more precise navigated drug delivery in cancer based on
innovative tools.
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